Transthyretin Amyloid Cardiomyopathy DOI
Paschalis Karakasis

JACC Advances, Journal Year: 2025, Volume and Issue: 4(5), P. 101726 - 101726

Published: April 25, 2025

Language: Английский

Sodium‐glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta‐analysis DOI Creative Commons
Paschalis Karakasis, Panagiotis Theofilis, Dimitrios Patoulias

et al.

European Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

Abstract Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) commonly leads to heart failure but has traditionally been an exclusion criterion in randomized clinical trials (RCTs) of sodium‐glucose cotransporter 2 inhibitors (SGLT2i); therefore, the effects these drugs this population remain undocumented. In light recent studies, meta‐analysis aimed investigate effect SGLT2i on prognosis patients with ATTR‐CM. Methods A comprehensive search Medline, Scopus, and Cochrane Library was conducted up November 17, 2024. Study selection, data extraction quality assessment were carried out independently by two investigators. Associations outcomes pooled using random‐effects meta‐analyses. Results total five studies (9766 participants, 4 propensity score‐matched) included. The use associated significant reductions all‐cause mortality [hazard ratio (HR) .54, 95% confidence interval (CI) .44–.66], cardiovascular (HR .39, CI .23–.65), major adverse events .71, .61–.83), hospitalizations (HFHs) .63, .52–.77) compared non‐use. odds cardiac arrhythmias significantly lower among users non‐users [odds (OR) .73, .65–.83]. Specifically, atrial fibrillation (AF) (OR .75, .62–.91), ventricular tachycardia .72, .59–.88), sudden arrest .50–.99). Conclusions SGLT2is may be a more favourable Adequately powered, long‐term RCTs are required validate available observational evidence.

Language: Английский

Citations

1
Sodium Glucose Cotransporter 2 inhibitors in Patients with Amyloidosis With or Without Heart Failure DOI Creative Commons
Silvio Nunes Augusto, Rochell Issa, Simon Vanhentenrijk

et al.

The American Journal of Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

1
Tolerance of Guideline-Directed Medical Therapy—Reply DOI
A. A. Ayoola, Alison Ohringer, Oanh Kieu Nguyen

et al.

JAMA Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals Network Open Cardiology Dermatology Health Forum Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2025 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal

Language: Английский

Citations

0
The Potential Role of SGLT2 Inhibitors in the Management of Amyloidosis DOI
Bülent Özlek

The American Journal of the Medical Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Sodium-glucose cotransporter 2 inhibitors in transthyretin amyloid cardiomyopathy: navigating potential benefits and uncertainties DOI

Paschalis Karakasis

Current Medical Research and Opinion, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 9

Published: April 18, 2025

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have garnered attention for their potential role in managing transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive condition characterized by significant morbidity and mortality. ATTR-CM remains underdiagnosed despite advances diagnostic modalities. While tafamidis acoramidis emerged as effective therapies, residual cardiovascular risk persists, highlighting the need adjunctive treatments. SGLT2i, initially developed antidiabetic agents, demonstrated cardioprotective effects various heart failure phenotypes, including preserved reduced ejection fractions. Emerging evidence suggests utility ATTR-CM, potentially addressing unmet needs such symptom burden, hospitalizations, survival. Clinical studies indicate that SGLT2i reduce all-cause mortality, major adverse cardiac events (MACE), with benefits extending to mortality improved functional status. Moreover, these agents appear mitigate arrhythmic complications, evidenced cardioversion procedures antiarrhythmic therapy requirements. Observational also highlight synergy of tafamidis, suggesting additive deposition failure. However, limitations, absence randomized controlled trials, immortal time bias, population heterogeneity, necessitate further research. Future directions involve elucidating mechanisms action, exploring personalized treatment strategies, leveraging big data analytics real-world insights. SGLT2i's transform management underscores promise, though robust trials are imperative validate findings optimize clinical applications.

Language: Английский

Citations

0
SGLT‐2 inhibitors for cardiac amyloidosis: Hype or hope? DOI Creative Commons
Flavio Tangianu,

Eleonora Nicolini,

Francesco Dentali

et al.

European Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Language: Английский

Citations

0
Reply DOI
Vikash Jaiswal, Muhammad Hanif, Yusra Mashkoor

et al.

JACC Advances, Journal Year: 2025, Volume and Issue: 4(5), P. 101696 - 101696

Published: April 25, 2025

Citations

0
Transthyretin Amyloid Cardiomyopathy DOI
Paschalis Karakasis

JACC Advances, Journal Year: 2025, Volume and Issue: 4(5), P. 101726 - 101726

Published: April 25, 2025

Language: Английский

Citations

0